Nicotinamide Riboside Supplementation Restores Myocardial Nicotinamide Adenine Dinucleotide Levels, Improves Survival, and Promotes Protective Environment Post Myocardial Infarction - Signalisation et physiopathologie cardiovasculaire Accéder directement au contenu
Article Dans Une Revue Cardiovascular Drugs and Therapy Année : 2023

Nicotinamide Riboside Supplementation Restores Myocardial Nicotinamide Adenine Dinucleotide Levels, Improves Survival, and Promotes Protective Environment Post Myocardial Infarction

Cynthia Tannous
  • Fonction : Auteur
Rana Ghali
  • Fonction : Auteur
Ahmed Karoui
  • Fonction : Auteur
Nada Habeichi
  • Fonction : Auteur
Ghadir Amin
  • Fonction : Auteur
George Booz
  • Fonction : Auteur
Marwan Refaat
  • Fonction : Auteur
Fouad Zouein

Résumé

Aims: Myocardial infarction (MI) is a major cause of death. Nicotinamide adenine dinucleotide (NAD+) is a coenzyme in oxidative phosphorylation and substrate of sirtuins and poly-ADP ribose polymerases, enzymes critical for cardiac remodeling post-MI. Decreased NAD+ is reported in several heart failure models with paradoxically an upregulation of nicotinamide riboside kinase 2, which uses nicotinamide riboside (NR) as substrate in an NAD+ biosynthetic pathway. We hypothesized that stimulating nicotinamide riboside kinase 2 pathway by NR supplementation exerts cardioprotective effects. Methods and results: MI was induced by LAD ligation in 2-3-month-old male mice. NR was administered daily (1 µmole/g body weight) over 7 days. RT-PCR showed a 60-fold increase in nicotinamide riboside kinase 2 expression 4 days post-MI with a 60% drop in myocardial NAD+ and overall survival of 61%. NR restored NAD+ levels and improved survival to 92%. Assessment of respiration in cardiac fibers revealed mitochondrial dysfunction post-MI, and NR improved complexes II and IV activities and citrate synthase activity, a measure of mitochondrial content. Additionally, NR reduced elevated PARP1 levels and activated a type 2 cytokine milieu in the damaged heart, consistent with reduced early inflammatory and pro-fibrotic response. Conclusion: Our data show that nicotinamide riboside could be useful for MI management.
Fichier principal
Vignette du fichier
Mathias Cv Drugs Therapy 2023 HAL.pdf (731.16 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04435969 , version 1 (07-03-2024)

Identifiants

Citer

Cynthia Tannous, Rana Ghali, Ahmed Karoui, Nada Habeichi, Ghadir Amin, et al.. Nicotinamide Riboside Supplementation Restores Myocardial Nicotinamide Adenine Dinucleotide Levels, Improves Survival, and Promotes Protective Environment Post Myocardial Infarction. Cardiovascular Drugs and Therapy, 2023, ⟨10.1007/s10557-023-07525-1⟩. ⟨hal-04435969⟩
35 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More